Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic                     Castration-resistant Prostate Cancer

Gafita, Andrei; Djaileb, Loïc; Rauscher, Isabel; Fendler, Wolfgang P.; Hadaschik, Boris; Rowe, Steven P.; Herrmann, Ken; Calais, Jérémie; Rettig, Matthew B.; Eiber, Matthias; Weber, Manuel; Benz, Matthias; Farolfi, Andrea

doi:10.1148/radiol.222148

Cited by 34 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RECIP (Response Evaluation Criteria In PSMA Imaging) 1.0 integrates both the WB PSMA TV changes, as assessed quantitatively, and the appearance of new lesions (Table 3). RECIP 1.0 is a biomarker that is prognostic for overall survival after 177 Lu-PSMA (58,59) and potentially also under other systemic therapies, such as chemo-or AR-targeted therapies (60). RECIP 1.0 was reported to be more reproducible than RECIST 1.1, aPCWG3, aPERCIST (PET Response Criteria in Solid Tumors), and PPP (60).…”

Section: Psma-targeted Pet Radioligands: Future Directionsmentioning

confidence: 99%

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer

Unterrainer,

Calais,

Bander

2024

Annu. Rev. Med.

Self Cite

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular-weight radioligands due to its extracellular portion. Successful targeting of PSMA began with the development of humanized J591 antibody. Due to their faster clearance compared to antibodies, small-molecule radioligands for targeted imaging and therapy of PC have been favored in recent development efforts. PSMA positron emission tomography (PET) imaging has higher diagnostic performance than conventional imaging for initial staging of high-risk PC and biochemical recurrence detection/localization. However, it remains to be demonstrated how to integrate PSMA PET imaging for therapy response assessment and as an outcome endpoint measure in clinical trials. With the recent approval of 177Lu-PSMA-617 by the US Food and Drug Administration for metastatic castration-resistant PC progressing after chemotherapy, the high value of PSMA-targeted therapy was confirmed. Compared to standard of care, PSMA-based radioligand therapy led to a better outcome and a higher quality of life. This review, focusing on the advanced PC setting, provides an overview of different approved and nonapproved PSMA-targeted imaging and therapeutic modalities and discusses the future of PSMA-targeted theranostics, also with an outlook on non-radiopharmaceutical-based PSMA-targeted therapies.

show abstract

Section: Psma-targeted Pet Radioligands: Future Directionsmentioning

confidence: 99%

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer

Unterrainer,

Calais,

Bander

2024

Annu. Rev. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…It represents, nowadays, the gold standard for staging highrisk patients [69], biochemical recurrence [70,71], and radioligand therapy selection [72]. There is also preliminary evidence regarding the potential of PSMA PET in PCa biopsy guidance [73,74] and response assessment in several therapeutic settings [75,76].…”

Section: Perspectives and Conclusionmentioning

confidence: 99%

Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals

Miceli,

Liberini,

Pepe

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Background: Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein overexpressed on the surface of tumor cells in most of the patients affected by prostate adenocarcinoma (PCa). However, PSMA expression has also been demonstrated in the endothelial cells of newly formed vessels of various solid tumors, suggesting a role for PSMA in neoangiogenesis. In this scenario, gallium-68 (68Ga) or fluoro-18 (18F)-labeled PSMA positron emission tomography (PET) may play a role in tumors other than PCa, generally evaluated employing other radiopharmaceuticals targeting different pathways. This review aims to investigate the detection rate of PSMA-PET compared to other radiopharmaceuticals (especially [18F]FDG) in non-prostate tumors to identify patients who may benefit from the use of such a theragnostic agent. Methods: We performed a bibliographic search on three different databases until February 2024 using the following terms: “positron emission tomography”, “PET”, “PET/CT”, “Prostate-specific membrane antigen”, “PSMA”, “non-prostate”, “not prostate cancer”, “solid tumor”, “FDG”, “Fluorodeoxyglucose”, “FAPi”, “FET”, “MET”, “DOPA”, “choline”, “FCH”, “FES”, “DOTATOC”, “DOTANOC”, and “DOTATATE”. Only original articles edited in English with at least 10 patients were included. Results: Out of a total of 120 articles, only 25 original articles comparing PSMA with other radiotracers were included in this study. The main evidence was demonstrated in renal cell carcinoma, where PSMA showed a higher detection rate compared to [18F]FDG PET/CT, with implications for patient management. PSMA PET may also improve the assessment of other entities, such as gliomas, in defining regions of early neoangiogenesis. Further data are needed to evaluate the potential role of PSMA-PET in triple-negative breast cancer as a novel therapeutic vascular target. Finally, unclear applications of PSMA-PET include thyroid and gastrointestinal tumors. Conclusions: The present review shows the potential use of PSMA-labeled PET/CT in solid tumors beyond PCa, underlining its value over other radiopharmaceuticals (mainly [18F]FDG). Prospective clinical trials with larger sample sizes are crucial to further investigate these possible clinical applications.

show abstract

“…Meanwhile, multiparametric MRI (mpMRI), various tracer-based nuclear medicine imaging techniques, and other imaging modalities have been implemented for post-radiotherapy assessment. However, current clinical imaging guidelines 3 , 4 , such as Response Evaluation Criteria in Solid tumours (RECIST), and RECIST for intratumoral therapies (itRECIST) and immunotherapy (iRECIST), fail to meet the requirements of therapy-specific and timely evaluation of routine and/or emerged combinational radiotherapies (i.e., radio-immunotherapy) 5 , 6 , whose response patterns may vary from previously well-established one. In this context, novel advanced imaging tools in three main steps in combinational radiotherapies, namely radiotherapy planning, patient stratification, and response/toxicity assessment, are in urgent need 7 .…”

Section: Introductionmentioning

confidence: 99%

Biomarker-driven molecular imaging probes in radiotherapy

Li,

Gong,

Luo

2024

Theranostics

View full text Add to dashboard Cite

Background: Biomarker-driven molecular imaging has emerged as an integral part of cancer precision radiotherapy. The use of molecular imaging probes, including nanoprobes, have been explored in radiotherapy imaging to precisely and noninvasively monitor spatiotemporal distribution of biomarkers, potentially revealing tumor-killing mechanisms and therapy-induced adverse effects during radiation treatment. Methods: We summarized literature reports from preclinical studies and clinical trials, which cover two main parts: 1) Clinically-investigated and emerging imaging biomarkers associated with radiotherapy, and 2) instrumental roles, functions, and activatable mechanisms of molecular imaging probes in the radiotherapy workflow. In addition, reflection and future perspectives are proposed. Results: Numerous imaging biomarkers have been continuously explored in decades, while few of them have been successfully validated for their correlation with radiotherapeutic outcomes and/or radiation-induced toxicities. Meanwhile, activatable molecular imaging probes towards the emerging biomarkers have exhibited to be promising in animal or small-scale human studies for precision radiotherapy. Conclusion: Biomarker-driven molecular imaging probes are essential for precision radiotherapy. Despite very inspiring preliminary results, validation of imaging biomarkers and rational design strategies of probes await robust and extensive investigations. Especially, the correlation between imaging biomarkers and radiotherapeutic outcomes/toxicities should be established through multi-center collaboration involving a large cohort of patients.

show abstract

Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer

Cited by 34 publications

References 10 publications

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer

Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals

Biomarker-driven molecular imaging probes in radiotherapy

Contact Info

Product

Resources

About